Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 14
1987 19
1988 7
1989 13
1990 20
1991 37
1992 25
1993 21
1994 25
1995 26
1996 23
1997 21
1998 24
1999 28
2000 27
2001 26
2002 19
2003 33
2004 38
2005 34
2006 46
2007 37
2008 46
2009 30
2010 35
2011 31
2012 37
2013 46
2014 23
2015 35
2016 39
2017 46
2018 27
2019 26
2020 43
2021 32
2022 30
2023 34
2024 37
2025 41
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,136 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis in Vietnam.
Fox GJ, Nhung NV, Cam Binh N, Hoa NB, Garden FL, Benedetti A, Ngoc Yen P, Cuong NK, MacLean EL, Yapa HM, Dowdy DW, Lan NH, Guevara-Rattray E, Duc Cuong P, Solomon O, Behr MA, Marais BJ, Graham SM, Menzies D, Thu Anh N, Marks GB. Fox GJ, et al. N Engl J Med. 2024 Dec 19;391(24):2304-2314. doi: 10.1056/NEJMoa2314325. N Engl J Med. 2024. PMID: 39693541 Clinical Trial.
Adverse events of any grade were reported in 306 participants (31.9%) taking levofloxacin and 125 (13.0%) taking placebo (risk difference, 18.9 percentage points; 95% CI, 14.2 to 23.6). ...CONCLUSIONS: Although the incidence of tuberculosis was lower in the levofloxacin …
Adverse events of any grade were reported in 306 participants (31.9%) taking levofloxacin and 125 (13.0%) taking placebo (risk differ …
Levofloxacin Preventive Treatment in Children Exposed to MDR Tuberculosis.
Hesseling AC, Purchase SE, Martinson NA, Fairlie L, Schaaf HS, Brigden J, Staples S, Gibb DM, Garcia-Prats A, Conradie F, McGowan C, Layton C, Batist E, Demers AM, Nyamathe S, Frigati L, Turner R, Duong T, Seddon JA. Hesseling AC, et al. N Engl J Med. 2024 Dec 19;391(24):2315-2326. doi: 10.1056/NEJMoa2314318. N Engl J Med. 2024. PMID: 39693542 Clinical Trial.
At least 80% of the assigned doses of levofloxacin or placebo were received by 86% of the participants in each trial group. By week 48, tuberculosis had developed in 5 participants (1.1%) in the levofloxacin group and in 12 participants (2.6%) in the placebo group ( …
At least 80% of the assigned doses of levofloxacin or placebo were received by 86% of the participants in each trial group. By week 4 …
Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysis.
Hong TC, El-Omar EM, Kuo YT, Wu JY, Chen MJ, Chen CC, Fang YJ, Leow AHR, Lu H, Lin JT, Tu YK, Yamaoka Y, Wu MS, Liou JM; Asian Pacific Alliance on Helicobacter and Microbiota. Hong TC, et al. Lancet Gastroenterol Hepatol. 2024 Jan;9(1):56-67. doi: 10.1016/S2468-1253(23)00281-9. Epub 2023 Nov 14. Lancet Gastroenterol Hepatol. 2024. PMID: 37972625
Studies investigating primary H pylori resistance to clarithromycin, metronidazole, levofloxacin, amoxicillin, or tetracycline in individuals naive to eradication therapy in the Asia-Pacific region (as defined by the UN geoscheme) were eligible for inclusion. ...From 1990 …
Studies investigating primary H pylori resistance to clarithromycin, metronidazole, levofloxacin, amoxicillin, or tetracycline in ind …
Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).
Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Wagenlehner FM, et al. Lancet. 2015 May 16;385(9981):1949-56. doi: 10.1016/S0140-6736(14)62220-0. Epub 2015 Apr 27. Lancet. 2015. PMID: 25931244 Clinical Trial.
Ceftolozane-tazobactam was non-inferior to levofloxacin for composite cure (306 [76.9%] of 398 vs 275 [68.4%] of 402, 95% CI 2.3-14.6) and, as the lower bound of the two-sided 95% CI around the treatment difference was positive and greater than zero, superiority was indica …
Ceftolozane-tazobactam was non-inferior to levofloxacin for composite cure (306 [76.9%] of 398 vs 275 [68.4%] of 402, 95% CI 2.3-14.6 …
Parenteral ofloxacin in treatment of pyelonephritis.
Cox CE. Cox CE. Urology. 1991;37(3 Suppl):16-20. doi: 10.1016/0090-4295(91)80091-k. Urology. 1991. PMID: 2003340 Clinical Trial.
In the first study intravenous (IV) ofloxacin was given to 34 patients with urine-culture-positive pyelonephritis. After three days of intravenous therapy patients could be switched to oral ofloxacin. Microbiologic eradication occurred in 97 percent and clinical cur …
In the first study intravenous (IV) ofloxacin was given to 34 patients with urine-culture-positive pyelonephritis. After three days o …
A Meta-Analysis of Levofloxacin for Contacts of Multidrug-Resistant Tuberculosis.
Duong T, Brigden J, Simon Schaaf H, Garden F, Marais BJ, Anh Nguyen T, White IR, Gibb DM, Nhung NV, Martinson NA, Fairlie L, Martinez L, Layton C, Benedetti A, Marks GB, Turner RM, Seddon JA, Hesseling AC, Fox GJ. Duong T, et al. NEJM Evid. 2025 Jan;4(1):EVIDoa2400190. doi: 10.1056/EVIDoa2400190. Epub 2024 Dec 18. NEJM Evid. 2025. PMID: 39693627
METHODS: We conducted combined analyses of two phase 3 trials of levofloxacin MDR-TB preventive treatment - Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis (VQUIN) trial and the Levofloxacin preventive treatment in children exposed to MDR- …
METHODS: We conducted combined analyses of two phase 3 trials of levofloxacin MDR-TB preventive treatment - Levofloxacin for t …
A systematic review and meta-analysis of comparative clinical studies on antibiotic treatment of brucellosis.
Maduranga S, Valencia BM, Li X, Moallemi S, Rodrigo C. Maduranga S, et al. Sci Rep. 2024 Aug 16;14(1):19037. doi: 10.1038/s41598-024-69669-w. Sci Rep. 2024. PMID: 39152180 Free PMC article.
Standard dual therapy with doxycycline + rifampicin had a higher risk of treatment failure compared to triple therapy which added streptomycin (RR: 1.98, 95% CI 1.17-3.35, p = 0.01) or levofloxacin (RR: 2.98, 95% CI 1.67-5.32, p = 0.0002), but a similar or lower risk compa …
Standard dual therapy with doxycycline + rifampicin had a higher risk of treatment failure compared to triple therapy which added streptomyc …
The effect of food or milk on the absorption kinetics of ofloxacin.
Dudley MN, Marchbanks CR, Flor SC, Beals B. Dudley MN, et al. Eur J Clin Pharmacol. 1991;41(6):569-71. doi: 10.1007/BF00314986. Eur J Clin Pharmacol. 1991. PMID: 1815968 Clinical Trial.
We have studied the effects of food or milk on the absorption of ofloxacin in 21 healthy male volunteers in a three-way crossover design. Milk did not alter the rate or extent of absorption of ofloxacin or its elimination. ...However, the extent of absorption and th …
We have studied the effects of food or milk on the absorption of ofloxacin in 21 healthy male volunteers in a three-way crossover des …
Antibiotic resistance of Helicobacter pylori in Mainland China: A focus on geographic differences through systematic review and meta-analysis.
Zeng S, Kong Q, Wu X, Duan M, Nan X, Yang X, Zuo X, Li Y, Li Y. Zeng S, et al. Int J Antimicrob Agents. 2024 Nov;64(5):107325. doi: 10.1016/j.ijantimicag.2024.107325. Epub 2024 Sep 6. Int J Antimicrob Agents. 2024. PMID: 39245326
The overall resistance rates of H. pylori in mainland China were 30.72% (95% CI 27.53%-33.99%) to clarithromycin, 70.14% (95% CI 29.53%-37.46%) to metronidazole and 32.98% (95% CI 28.73%-37.37%) to levofloxacin; for amoxicillin, tetracycline, and furazolidone, the rates we …
The overall resistance rates of H. pylori in mainland China were 30.72% (95% CI 27.53%-33.99%) to clarithromycin, 70.14% (95% CI 29.53%-37.4 …
Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial.
Drayson MT, Bowcock S, Planche T, Iqbal G, Pratt G, Yong K, Wood J, Raynes K, Higgins H, Dawkins B, Meads D, Hulme CT, Monahan I, Karunanithi K, Dignum H, Belsham E, Neilson J, Harrison B, Lokare A, Campbell G, Hamblin M, Hawkey P, Whittaker AC, Low E, Dunn JA; TEAMM Trial Management Group and Trial Investigators. Drayson MT, et al. Lancet Oncol. 2019 Dec;20(12):1760-1772. doi: 10.1016/S1470-2045(19)30506-6. Epub 2019 Oct 23. Lancet Oncol. 2019. PMID: 31668592 Free PMC article. Clinical Trial.
FINDINGS: Between Aug 15, 2012, and April 29, 2016, we enrolled and randomly assigned 977 patients to receive levofloxacin prophylaxis (489 patients) or placebo (488 patients). Median follow-up was 12 months (IQR 8-13). 95 (19%) first febrile episodes or deaths occurred in …
FINDINGS: Between Aug 15, 2012, and April 29, 2016, we enrolled and randomly assigned 977 patients to receive levofloxacin prophylaxi …
1,136 results